27/07/2015 23:28:27 Free Membership Login

Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
07/27/20155:10PMDJNMylan's Leverage to Resist Teva Deal Reveals Shift in Rules
By Shayndi Raice And Liz Hoffman In May, Mylan NV's executive team met with investors in a Manhattan conference room. As shareholders complained about the drug maker's resistance to a $40 billion takeover proposal from Teva Pharmaceutical Industries Ltd., Executive Chairman Robert Coury leaned across the table. "This is... More...>>
07/27/20153:58PMPRNUSMylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders
Mylan Announces Meeting Date and Record Date of Extraordinary General Meeting of Shareholders PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that it will hold its extraordinary general meeting... More...>>
07/27/201510:11AMDJNTeva to Buy Allergan Generics for $40.5 Billion -- 7th Update
By Jonathan D. Rockoff, Dana Mattioli and Liz Hoffman Teva Pharmaceutical Industries Ltd. on Monday agreed to buy Allergan PLC's generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the top ranks of global drug makers. Teva said Allergan would receive $33.75 billion in cash... More...>>
07/27/20159:01AMDJNTeva to Buy Allergan Generics for $40.5 Billion -- 6th Update
By Jonathan D. Rockoff, Dana Mattioli and Liz Hoffman Teva Pharmaceutical Industries Ltd. on Monday agreed to buy Allergan PLC's generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the top ranks of global drug makers. Teva said Allergan would receive $33.75 billion in cash... More...>>
07/27/20158:35AMDJNTeva to Buy Allergan Generics for $40.5 Billion -- 5th Update
By Jonathan D. Rockoff, Dana Mattioli and Liz Hoffman Teva Pharmaceutical Industries Ltd. on Monday agreed to buy Allergan PLC's generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the top ranks of global drug makers. Teva said Allergan would receive $33.75 billion in cash... More...>>
07/27/20156:42AMPRNUSMylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit
Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 HERTFORDSHIRE, England and PITTSBURGH, July 27, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement regarding Teva's (NYSE and TASE: TEVA) announcement... More...>>
07/27/20156:30AMDJNTeva to Buy Allergan Generics for $40.5 Billion
Teva Pharmaceutical Industries Ltd. on Monday said it would buy Allergan PLC's generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the top ranks of global drug makers. Teva said Allergan would receive $33.75 billion in cash and Teva shares valued at $6.75 billion, giving... More...>>
07/25/20159:13PMDJNTeva in Talks to Buy Allergan's Generics Unit -- 4th Update
By Dana Mattioli, Jonathan D. Rockoff, Dana Cimilluca and Liz Hoffman Israeli drug maker Teva Pharmaceutical Industries Ltd. is in talks to combine with Allergan PLC's big generic-drug business, in a move that would further consolidation in the health-care industry and likely mean the end of Teva's pursuit of another acquisition... More...>>
07/24/20153:28PMPRNUSMylan Schedules Second Quarter 2015 Financial Results Conference Call and Live Webcast
Mylan Schedules Second Quarter 2015 Financial Results Conference Call and Live Webcast PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 24, 2015 HERTFORDSHIRE, England and PITTSBURGH, July 24, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL), a leading global pharmaceutical company, announced today that it will host... More...>>
07/23/201512:20PMDJNDrugmaker Mylan Uses Dutch Foundation to Fend Off Hostile Bid
A foundation set up by pharmaceutical firm Mylan NV on Thursday triggered a Dutch variation on a poison pill to fend off a takeover proposal by Israeli rival Teva Pharmaceutical Industries Ltd. The foundation, called a "stichting" in Dutch, has the option to temporarily obtain preferred shares with special voting rights... More...>>
07/23/20158:47AMPRNUSMylan Acknowledges Exercise of Full Call Option by the Independent Foundation
Mylan Acknowledges Exercise of Full Call Option by the Independent Foundation PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 23, 2015 HERTFORDSHIRE, England and PITTSBURGH, July 23, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today acknowledged the exercise of the full call option by Stichting Preferred Shares... More...>>
07/22/201510:00AMDJNAbbott Labs Profit Beats Expectations
Abbott Laboratories Inc. said its profit climbed 68% in the latest quarter on robust sales in its established pharmaceutical products segment and a gain on the sale of a portion of Mylan N.V. stock. "We've achieved another quarter of strong sales growth led by our global diagnostics and branded generics businesses," said... More...>>
07/14/20157:30AMPRNUSMylan One of First to Launch Generic Version of Namenda® Tablets
Mylan One of First to Launch Generic Version of Namenda® Tablets - Company awarded 180 days shared marketing exclusivity - PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 14, 2015 HERTFORDSHIRE, England and PITTSBURGH, July 14, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Memantine... More...>>
07/09/20157:30AMPRNUSMylan Launches First Generic Targretin® Capsules
Mylan Launches First Generic Targretin® Capsules - 180 days of marketing exclusivity awarded- PR Newswire HERTFORDSHIRE, England and PITTSBURGH, July 9, 2015 HERTFORDSHIRE, England and PITTSBURGH, July 9, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Bexarotene 75mg Capsules, which... More...>>
07/06/20151:06PMDJNTeva May Raise Offer for Mylan to Range of $86 to $88 a Share -Bloomberg
Teva Pharmaceutical Industries Ltd. (TEVA.TV, TEVA), which launched a $40 billion bid for Mylan NV (MYL) in April, plans to increase the value of its offer, Bloomberg News reported Monday, citing people with knowledge of the matter. Teva's offer is worth $82 a share. Bloomberg reported that a new bid may be worth $86 to... More...>>
06/19/20159:30AMDJNTeva Takes 4.6% Stake in Mylan
Teva Pharmaceutical Industries Ltd. said it has taken a 4.61% stake in Mylan NV, an amount that gives Teva standing in the Dutch Enterprise Chamber to commence a takeover if necessary. Teva is in the process of trying to buy Mylan, as Mylan itself has made moves to purchase Perrigo Co. Mylan executives have sharply rebuffed... More...>>
06/18/20153:50PMDJNTeva's Copaxone Patent Loses Again
The U.S. Court of Appeals has again ruled that Teva Pharmaceuticals Ltd.'s patent for its blockbuster multiple-sclerosis treatment Copaxone is invalid. Shares of Teva fell about 2% in midday trading. A spokesperson said that Teva is "committed to pursuing all legal pathways including seeking further appellate review... More...>>
06/18/201511:55AMPRNUSU.S. Court of Appeals for the Federal Circuit Finds Teva's '808 Copaxone® Patent Invalid
U.S. Court of Appeals for the Federal Circuit Finds Teva's '808 Copaxone® Patent Invalid Ruling deals yet another blow to Teva's future financial prospects PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 18, 2015 HERTFORDSHIRE, England and PITTSBURGH, June 18, 2015 /PRNewswire/ -- Mylan N.V. (Nasdaq: MYL) today... More...>>
06/16/20159:19AMPRNUSMylan Issues Statement in Response to Abbott's Support for Perrigo Transaction
Mylan Issues Statement in Response to Abbott's Support for Perrigo Transaction PR Newswire HERTFORDSHIRE, England and PITTSBURGH, June 16, 2015 HERTFORDSHIRE, England and PITTSBURGH, June 16, 2015 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement regarding Abbott Laboratories' (NYSE: ABT) announced... More...>>
06/16/20158:42AMPRNUSPulmatrix and Mylan Enter Into ex-U.S. Development Agreement for PUR0200
Pulmatrix and Mylan Enter Into ex-U.S. Development Agreement for PUR0200 PR Newswire LEXINGTON, Mass. and HERTFORDSHIRE, England and PITTSBURGH, June 16, 2015 LEXINGTON, Mass. and HERTFORDSHIRE, England and PITTSBURGH, June 16, 2015 /PRNewswire/ -- Pulmatrix (Nasdaq: PULM), a clinical stage biopharmaceutical company developing... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq myl150727 23:28